BACKGROUND: Abnormal methylation of urinary @entity8945 and @entity21510 conferred high sensitivity and specificity for the detection of @entity189 . OBJECTIVE: We examine the performance of the urine-based @entity8945 / @entity21510 methylation assay with the addition of urine cytology for the detection of @entity189 . MATERIALS AND METHODS: A prospective multi-institutional study was conducted to assess the performance of a methylation assay for @entity1 with @entity811 or under surveillance for non-muscle invasive @entity150 (NMIBC). All @entity1 underwent cystoscopy, a methylation assay, and cytology. Receiver operator characteristic (ROC) curves were constructed for cytology alone, the methylation assay alone, and a combined model. Areas under the curve (AUC) were compared using likelihood ratio tests. RESULTS: A total of 172 @entity1 were enrolled (37% for @entity811 and 63% NMIBC). The AUC for cytology alone with equivocal cytologies positive was 0.704, and improved to 0.773 with the addition of the DNA methylation assay (p < 0.001). When the equivocal cytologies were considered negative, the AUC improved from 0.558 to 0.697 with the addition of the DNA methylation assay (p = 0.003). CONCLUSIONS: Addition of a @entity8945 / @entity21510 -based DNA methylation assay adds diagnostic value to urine cytology and the model is sensitive to the classification of equivocal cytology.

Urinary @entity21510 and XXXX methylation to augment conventional urine cytology for the detection of @entity150 .

@entity1 :: ('9606', 'Species') :: ['patients'] @entity21510 :: ('22795', 'Gene') :: ['NID2'] @entity189 :: ('MESH:D002277', 'Disease') :: ['urothelial carcinoma'] @entity150 :: ('MESH:D001749', 'Disease') :: ['bladder cancer'] @entity8945 :: ('7291', 'Gene') :: ['TWIST1'] @entity811 :: ('MESH:D006417', 'Disease') :: ['hematuria']
@entity8945 :: (7291,Gene) :: ['TWIST1']
